News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

4SC AG Spins Off quattro research GmbH - A Company Which Develops And Markets Software Solutions For The Life Science Industry

10/19/2005 5:10:05 PM

MARTINSRIED, Germany, Feb. 23 /PRNewswire/ -- 4SC AG, a drug discovery and development company specialising in the research and development of therapeutic agents, announced today the spin-off of an independent company, quattro research GmbH. The new company develops and markets software solutions for the integration of chemical and biological data in drug discovery and development. quattro research draws on expertise and software developments within 4SC AG. The proprietary technology 4SCan(R) for the virtual screening of large data sets does not constitute part of the spin-off.

"The software system quattro/Suite, for knowledge and data management in drug discovery and development, has been developed under realistic conditions, in close collaboration between our IT team and our scientists in the laboratory. It is an integral component of our efficient processes, and has demonstrated its effectiveness in all our therapeutic projects. It was, therefore, a logical move to make this software package available to a wide clientele in the Life Science industry by establishing quattro research GmbH," explained Dr. Ulrich Dauer, CEO of 4SC.

The quattro/Suite contains solutions for registering new chemical substances, for managing biological assay data, for stock management particularly for research laboratories, and an electronic laboratory notebook. The efficiency of the quattro products is a result of the integrated Chemistry Engine, which facilitates work with chemical structures in all areas of the software package. In addition to the quattro/Suite, quattro research GmbH also offers its customers consultancy services and specific system solutions to manage chemical and biological data.

The company began operating in January 2004, at its headquarters in Martinsried. 4SC has a 48.8% holding in the new company. The main shareholder, with a total of 51.2%, is the founder team of quattro research GmbH, Dr. Bernhard Schirm and Dr. Markus Weisser. Both act as Managing Directors of the company.

quattro research GmbH has already concluded a comprehensive contract with 4SC AG. This agreement, covering several years, relates to software developments and services in the IT sector.

"We are looking forward to working with life science companies, where the ability to extract specific information from enormous volumes of data, and to generate knowledge from it, will be an increasingly important success factor," commented Dr. Bernhard Schirm, Managing Director of quattro research GmbH, and former Head of IT at 4SC. "Our quattro/suite, which has been specially designed to satisfy the requirements of scientists in all disciplines of drug discovery and development, is ideally suited to meet this challenge."

About 4SC:

4SC is a drug discovery and development company that uses its cheminformatics-based technological platform for the discovery and development of new drug candidates. By combining the disciplines of chemistry and biology with the proprietary virtual High Throughput Screening technology, 4SCan(R), the time and cost of advancing a drug candidate to the development phase can be significantly reduced.

The company's therapeutic focus centres on infectious and hyperproliferative diseases. The first project for treatment of rheumatoid arthritis is currently in the clinical phase I stage of development. Four additional research projects in cancer indications, transplantation, cystic fibrosis, and ophthalmology are currently undergoing preclinical evaluation and pharmacokinetics studies. 4SC, which was founded in 1997, now employs 60 people and is based in Martinsried, near Munich, Germany. Further information about the company is available at


CONTACT: Bettina von Klitzing, 4SC AG, +49-89-700-763-0,; Dr. Bernhard Schirm, quattro research GmbH,+49-89-700-763-16,

Read at

comments powered by Disqus